2024-513519-28-00进行中（未招募）3 期
Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting19 个研究点 分布在 4 个国家目标入组 280 人开始时间: 2024年6月19日最近更新:
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 280
- 试验地点
- 19
- 主要终点
- EFS, defined as time from randomization to melanoma progression (irresectable stage III or stage IV disease), melanoma recurrence, treatment-related death, or melanoma-related death, whichever occurs first.
研究概览
简要总结
To compare the event-free survival (EFS) of neoadjuvant ipilimumab + nivolumab (followed by adjuvant nivolumab or dabrafenib + trametinib in patients not achieving a pathologic response) versus standard adjuvant nivolumab
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 0 years 至 64 years（18-64 Years, 0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Men and women, at least 16 years of age
- •Women of childbearing potential (WOCP) must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly, to avoid pregnancy during and until 23 weeks post last ipilimumab + nivolumab infusion
- •Males who are sexually active with WOCP are not required to use contraception during treatment with nivolumab +/- ipilimumab, but must use appropriate method(s) of contraception, i.e. methods with a failure rate of <1% per year when used consistently and correctly, to avoid pregnancy during and until 17 weeks post last dabrafenib + trametinib administration
- •Patient willing and able to understand the protocol requirements and comply with the treatment schedule, scheduled visits, electronic patient outcome reporting, tumor biopsies and extra blood withdrawal during screening and in case of recurrence, and other requirements of the study
- •Patient has signed the Informed Consent document
- •World Health Organization (WHO) Performance Status 0 or 1
- •Cytologically or histologically confirmed resectable stage III melanoma of cutaneous or unknown primary origin with one or more macroscopic lymph node metastases (clinical detectable), that can be biopsied and a maximum of 3 additional resectable in-transit metastases. A concurrent resectable primary melanoma is allowed. Clinical detectable lymph nodes are defined as either one: o a palpable node, confirmed as melanoma by pathology; o a non-palpable but enlarged lymph node according to RECISTv1.1 (at least 15 mm in short axis), confirmed as melanoma by pathology; o a PET scan positive lymph node of any size confirmed as melanoma by pathology;
- •No other malignancies, except adequately treated and with a cancer-related lifeexpectancy of more than 5 years
- •No prior immunotherapy targeting CTLA-4, PD-1, PD-L1 or LAG-3
- •No prior targeted therapy targeting BRAF and/or MEK
- •No immunosuppressive medications within 6 months prior study inclusion (steroids equivalent to prednisolone ≤10 mg are allowed);
- •Screening laboratory values must meet the following criteria: WBC ≥2.0x109/L, neutrophils ≥1.5x109/L, platelets ≥100x109/L, hemoglobin ≥5.5 mmol/L, creatinine ≤1.5xupper limit of normal (ULN), AST ≤1.5x ULN, ALT ≤1.5x ULN, bilirubin ≤1.5x ULN (except for subjects with Gilbert syndrome who must have a total bilirubin <3.0 mg/dL);
- •LDH level <1.5x ULN;
排除标准
- •Distantly metastasized melanoma;
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids >10 mg prednisolone daily equivalent;
- •Use of other investigational drugs before study drug administration 30 days or 5 half-times before study inclusion;
- •Psychological, familial, sociological, or geographical conditions that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
- •Women who are pregnant or breastfeeding;
- •Uveal/ocular or mucosal melanoma
- •In-transit metastases only (without cytological or histological proven lymph node involvement)
- •Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications. Subjects with resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are permitted to enroll;
- •Prior radiotherapy targeting the affected lymph node region(s);
- •Subjects will be excluded if they test positive for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. Subjects treated and being at least one year free from HCV are allowed to participate;
- •Subjects will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
- •Subjects with history of allergy to study drug components or history of severe hypersensitivity reaction to monoclonal antibodies.
- •Subjects with underlying medical conditions or active infection that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events;
结局指标
主要结局
EFS, defined as time from randomization to melanoma progression (irresectable stage III or stage IV disease), melanoma recurrence, treatment-related death, or melanoma-related death, whichever occurs first.
EFS, defined as time from randomization to melanoma progression (irresectable stage III or stage IV disease), melanoma recurrence, treatment-related death, or melanoma-related death, whichever occurs first.
次要结局
- Pathologic response rate (categorized into pCR, near-pCR, MPR, pPR, pNR, according to INMC criteria70, see 7.1.1) in the neoadjuvant arm;
- Correlation of pathologic response in the neoadjuvant arm to RFS, DMFS, and OS;
- OS, defined as time between date of randomization and date of death from any cause;
- RFS, defined as time between date of surgery and date of melanoma recurrence, treatment-related death or melanoma-related death, whichever occurs first;
- DMFS, defined as time between date of randomization and date of first distant metastasis, treatment-related death or melanoma-related death, whichever occurs first;
- EFS including new primary melanoma, defined as time from randomization to a new primary melanoma (excluding melanoma in situ), melanoma progression (irresectable stage III or stage IV disease), melanoma recurrence, treatment-related death, or melanoma-related death, whichever occurs first;
- Frequency and duration of all grade and grade 3-5 treatment-related adverse events according to CTCAE 5.0;
- Surgical complication rates according to Clavien-Dindo surgical classification;
- Quality of life as measured by EORTC QLQ C30, the Melanoma Subscale and Melanoma Surgery Subscale of FACT-M, the Cancer Worry Scale, HADS questionnaire, EQ-5D-5L, the immunotherapy-specific questionnaire, an assessment of work performance, sexual health, and Amsterdam Cognition Scan;
- Performing health technology assessments comparing the neoadjuvant arm with the standard adjuvant arm.
研究者
C.Blank
Scientific
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
研究点 (19)
Loading locations...
相似试验
招募中
1 期
Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab - NADINAResectable stage III cutaneous or unknown primary melanoma patients with one or more clinical detectable lymph node metastasis that can be biopsied.MedDRA version: 20.0Level: LLTClassification code 10027155Term: Melanoma skinSystem Organ Class: 100000004864EUCTR2021-001492-16-ITTHE NETHERLANDS CANCER INSTITUTE420
进行中（未招募）
1 期
Study in melanoma patients with lymph node metastases into treatment with ipilimumab and nivolumab before surgery compared to standard nivolumab treatment after surgery.Patients with stage III melanomaEUCTR2021-001492-16-PLStichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis420
招募中
3 期
Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINAmelanoma10040900skin cancerNL-OMON54313Antoni van Leeuwenhoek Ziekenhuis150
进行中（未招募）
1 期
ADINACTIS2024-513519-28-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting395
进行中（未招募）
1 期
A Study of Nivolumab Plus Bempegaldesleukin (bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded Into the Muscle Wall of the Bladder and Who Cannot get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.Muscle-Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002676-40-GRBristol-Myers Squibb International Corporation720